- Patent Title: miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL)
-
Application No.: US15173368Application Date: 2016-06-03
-
Publication No.: US09771585B2Publication Date: 2017-09-26
- Inventor: David Rodman , Anita Seto , Christina Dalby , Aimee Jackson , Xuan Beatty
- Applicant: miRagen Therapeutics, Inc.
- Applicant Address: US CO Boulder
- Assignee: MIRAGEN THERAPEUTICS, INC.
- Current Assignee: MIRAGEN THERAPEUTICS, INC.
- Current Assignee Address: US CO Boulder
- Agency: Cooley LLP
- Main IPC: C07H21/02
- IPC: C07H21/02 ; C07H21/04 ; C12N15/11 ; A61K48/00 ; C12N15/113
Abstract:
The present invention provides oligonucleotide inhibitors of miR-155 and compositions thereof. The invention further provides methods for treating cancer such as a T cell lymphoma in a subject by administering to the subject an oligonucleotide inhibitor of miR-155. The invention also provides methods for reducing or inhibiting the proliferation of malignant T cells by administering an oligonucleotide inhibitor of miR-155.
Public/Granted literature
- US20160355814A1 MIR-155 INHIBITORS FOR TREATING CUTANEOUS T CELL LYMPHOMA (CTCL) Public/Granted day:2016-12-08
Information query
